

## Info Sheet for Technical description

No. 0011 - 1

### Organization

\* Mandatory fields

Name of Organization*	REPROCELL Inc.	
Address, City, States, Zip, Country*	MetLife Shin-yokohama Bldg. 9F, 3-8-11 Shin-yokohama, Kohoku-ku, Yokohama, Kanagawa 222-0033, Japan	
URL	<a href="https://www.reprocell.com/">https://www.reprocell.com/</a>	
Brief Descriptions of Organization* (Approx. 100 words)	1) Research Support Business Manufacture and sale of reagents for iPS cell research Provision of drug discovery support services (i.e., establishment of iPS cell lines, CRO services, etc.) Provision of biological samples Provision of genetic analysis services	
Contact address	Name*	
	Department* / Position	
	E-mail* / TEL	

### What kind of technology do you want to offer? \*

- A.** Clinical Development Pipelines → Please see **Sheet [A]**
- B.** Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Services etc. → Please see **Sheet [B]**
- C.** Platform Technologies(\*) that are not included in the above (Group B) → Please see **Sheet [C]**
- \* Peripheral technologies that contribute to a significant improvement in productivity throughout the value chain of pharmaceuticals, from research and development to manufacturing and ultimately market launch.

### If you agree to the following, please check "Yes" below. \*

The technologies introduced in this 'Info Sheet' are in the public domain, as they have been published in research papers or have related patent applications.

- Yes

### Do you have any collaborations/partnerships with pharmaceutical companies?

- Yes
- No

### If you have already received funding from VCs or other sources, up to which stage has the investment round progressed?

- Angel / Seed (including AMED/JST grants)
- Series A
- Series B
- Series C
- Series D or further advanced stages

### Do you agree to leave your presentation materials at FIRM hands and entrust us to make use of them for the purpose of promoting your partnering opportunities? \*

Options*	Comments
<input checked="" type="checkbox"/> Yes	
<input type="checkbox"/> No	

Filled in by\*

Mitsuru Inamura

Date\*

09/22/2023

<b>Info Sheet for Technical overview</b>
--

No. 0011 - 1

\* Mandatoty fields

**Title\***

<b>Stemchymal MSC therapy</b>
-------------------------------

**Development Phase\***

- |   |   |   |
|---|---|---|
| <input type="checkbox"/> Basic Research           | <input type="checkbox"/> Drug Discovery                       | <input type="checkbox"/> Pre-Clinical               |
| <input type="checkbox"/> Clinical Trial (Phase I) | <input checked="" type="checkbox"/> Clinical Trial (Phase II) | <input type="checkbox"/> Clinical Trial (Phase III) |
| <input type="checkbox"/> Review                   | <input type="checkbox"/> Others                               |   |

**Disease Area\***

- |  |  |   |
|--|--|---|
| <input type="checkbox"/> Cancer          | <input checked="" type="checkbox"/> Central nervous system | <input type="checkbox"/> Ophthalmology  |
| <input type="checkbox"/> Musculoskeletal | <input type="checkbox"/> Endocrine / Metabolism            | <input type="checkbox"/> Cardiovascular |
| <input type="checkbox"/> Urogenital      | <input type="checkbox"/> Digestive organ                   | <input type="checkbox"/> Blood          |
| <input type="checkbox"/> Infection       | <input type="checkbox"/> Dermatology                       | <input type="checkbox"/> Immunity       |
| <input type="checkbox"/> Otolaryngology  | <input type="checkbox"/> Respiratory                       | <input type="checkbox"/> Others         |

**Description\***

Stemchymal is an allogeneic stem cell therapy, meaning it uses stem cells obtained from one patient to treat another.

The mesenchymal stem cells (MSCs) used to create Stemchymal are isolated from the adipose, or fatty, tissue of healthy individuals. Once isolated from this primary tissue using a unique cell processing system, the MSCs are administered to recipients by intravenous (IV) infusion.

As MSCs display low immunogenicity, they are less likely to cause an immune reaction in patients receiving treatment. These cells have also displayed therapeutic effects in vivo, with infusion shown to partially restore motor function in SCA mouse models.

Stemchymal was developed to treat spinocerebellar ataxia (SCA), a group of rare neurological diseases that have a significant impact on quality of life. The SCAs are caused by the degeneration of neurons in the central nervous system which leads to progressive in-coordination of gait and dysphagia. SCA occurs between the ages of 20 and 60 years old, and more than 30 disease subtypes have been identified so far. It is thought that there are over 30,000 patients living with SCA in Japan alone.

Unfortunately, there is presently no cure for SCA, and standard-of-care treatments have limited success. Stemchymal is the first regenerative therapeutic which has the potential to inhibit the progression of SCA and is currently being trailed in patients with SCA3 and SCA6

**Filled in by\***

Mitsuru Inamura

**Date\***

09/22/2023